Having trouble accessing articles? Reset your cache.

AVL-301: Phase I/II amended

Clovis disclosed in its 1Q13 earnings that it will transition to a tablet formulation of CO-1686 from a capsule formulation for all clinical trials, including an ongoing Phase I/II trial, starting in 3Q13. The decision is based on a study in healthy volunteers showing that the tablet formulation demonstrated plasma exposure levels about 3-fold greater than the capsule

Read the full 583 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers